Filing Flows › Arcturus Therapeutics Holdings (ARCT) › Q1 2026
Arcturus Therapeutics Holdings (ARCT) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 7, 2026
Arcturus Therapeutics Holdings (ARCT) reported revenue of $2.1M for the first quarter 2026 (Q1 2026), -93% from a year earlier and -71% from the quarter before.
Arcturus Therapeutics Holdings, Q1 2026: revenue $2.1M (-93% year over year), net loss $27.0M, operating cash flow −$19.4M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.1M | -71% | -93% |
| Operating profit | −$28.9M | — | — |
| Net earnings | −$27.0M | — | — |
| Operating cash flow | −$19.4M | — | — |
What changed
Revenue was $2.1M in Q1 2026, down 93% year over year and down 71% from the previous quarter. Grant was the largest line at 70% of revenue. Collaboration Revenue lost $24.9M year over year (down 98%), 91% of the total change.
Operating costs exceeded revenue by $28.9M, an operating margin of -1403.7%. Total costs fell 33% while revenue fell 93%. The quarter ended with a net loss of $27.0M, narrower than the previous quarter's $29.1M loss.
Operating cash flow was −$19.4M. Non-cash charges added back $658K of depreciation and amortization and $4.3M of share-based compensation. Working capital and other items added $2.5M.
Questions
What was Arcturus Therapeutics Holdings' revenue in the first quarter 2026?
Arcturus Therapeutics Holdings (ARCT) reported revenue of $2.1M for the first quarter 2026 (Q1 2026), -93% from a year earlier and -71% from the quarter before.